Who are Flamboyant 200/12's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Layla Tab., Pearlium/EffectiCal, Flamboyant 125/12.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/flamboyant-200-12.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Flamboyant 200/12 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Flamboyant 200/12 (Flamboyant 200/12) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker/beta blocker combination. Area: Cardiovascular.

phase 3 Calcium channel blocker/beta blocker combination Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Flamboyant 200/12 (Flamboyant 200/12) — EMS. Flamboyant 200/12 is a fixed-dose combination of a calcium channel blocker and a beta blocker.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Flamboyant 200/12 TARGET	Flamboyant 200/12	EMS	phase 3	Calcium channel blocker/beta blocker combination
Layla Tab.	Layla Tab.	Mather's Pharm. Co., Ltd.	marketed	Calcium channel blocker/beta blocker combination
Pearlium/EffectiCal	Pearlium/EffectiCal	University of Alberta	marketed	Calcium channel blocker/beta blocker combination
Flamboyant 125/12	Flamboyant 125/12	EMS	phase 3	Calcium channel blocker/beta blocker combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker/beta blocker combination class)

EMS · 2 drugs in this class
Mather's Pharm. Co., Ltd. · 1 drug in this class
University of Alberta · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Flamboyant 200/12 — Competitive Intelligence Brief. https://druglandscape.com/ci/flamboyant-200-12. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing